Nektar Therapeutics Inc (NKTR)

NKTR (NASDAQ:Drugs) EQUITY
$22.95
pos +0.71
+3.19%
Today's Range: 22.27 - 23.80 | NKTR Avg Daily Volume: 1,274,200
Last Update: 07/24/17 - 4:00 PM EDT
Volume: 2,957,308
YTD Performance: 81.26%
Open: $23.50
Previous Close: $22.24
52 Week Range: $9.16 - $17.55
Oustanding Shares: 155,149,696
Market Cap: 3,439,668,760
6-Month Chart
TheStreet Ratings Grade for NKTR
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 7
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.00 1.00 1.00 1.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -16.07
Price Earnings Comparisons:
NKTR Sector Avg. S&P 500
-16.07 0.00 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
21.07% 44.51% 103.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue -28.30 0.10 0.04
Net Income 0.00 -0.10 0.00
EPS 0.00 -0.20 0.00
Earnings for NKTR:
EBITDA -0.10B
Revenue 0.17B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $-0.34 $-0.17 $-1.16 $-1.06
Number of Analysts 5 5 6 6
High Estimate $-0.27 $0.33 $-0.61 $-0.60
Low Estimate $-0.40 $-0.35 $-1.46 $-1.50
Prior Year $-0.36 $-0.32 $-1.10 $-1.16
Growth Rate (Year over Year) 5.56% 45.63% -5.30% 8.35%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?
Biotech companies show more energy than the rest of the market Monday.
Finding the stocks that have changed direction.
This morning I warned about an overbought group of market sectors/leaders.   Thus far, (recent leaders) retail and financials are …

My Takeaways and Observations Real Money Pro($)

The U.S. dollar strengthened meaningfully. Any more strength will begin to raise concerns about multinational profits. The price of crude oil expanded by $0.80 to nearly $45/barrel. But, we are still in a short term downtrend. Gold fell be $23. I rebuilt my GLD position on the weakness. We are near the 200 day moving average. Ag commodities: wheat down $0.04, corn down $0.02, soybeans up $0.08 and oats are flat. Fertilizer stocks traded well today. Lumber up $1. Bonds got schmeissed. iShares Barclays 20+ Yr Treas.Bond ETF (TLT) down a beaner. The 10-year U.S. note yield rose by four basis points and the long bond by three basis points. The 2s/10s spread widened by two basis points to 101 basis points. Municipals were surprisingly weaker. Closed end muni bond funds flatlined. But high yield was much stronger iShares iBoxx $ High Yid Corp Bond ETF (HYG) +$1 and SPDR Barclays Capital High Yield Bnd ETF (JNK) +$0.40. Blackstone/GSO Strategic Credit Fund (BGB) +$0.13. Banks benefited from the steepening yield curve. I shorted JPMorgan Chase (JPM) , Citigroup (C) and Financial Select Sector SPDR Fund (XLF) late in the day. Insurance stocks were terrific. Long Hartford Financial (HIG) (large) looks like it might be breaking out. (I still owe you guys an analysis of the good quarter release from last week -- coming soon! Small shorts in Lincoln National (LNC) and Metlife (MET) , rose. Brokerages Morgan Stanley (MS) and Goldman Sachs (GS) were the "world's fair." Autos advanced. I remain short (small) General Motors (GM) and Ford (F) . Retail rebounded. My only long JC Penney (JCP) was punk (up a dime after being up three times that amount earlier in the day). Biotech was +3.5%. Allergan (AGN) , Celgene (CELG) ++ Speculative biotech (Portola Pharmaceuticals (PTLA)  , SAGE Therapeutics (SAGE) , Aerie Pharmaceuticals (AERI) ,  Nektar Therapeutics (NKTR

The Good, the Bad and the Ugly Real Money Pro($)

Mr. Market managed to make gains on top of yesterday's ramp, the first two-day, back-to-back rise in two weeks. My sense is that participants are again becoming complacent. Commodities (ag, lumber, gold and crude oil) were a strong asset class. Autos (General Motors (GM) ), and retail (JC Penney (JCP) +3.5%, Coach (COH) , Macy's (M) ) -- two lagging groups -- started to turn higher today. Junk bonds climbe
The big issue is if the market can build on Friday's jobs good news.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
Computer programming has found that buying bad-news dips is a consistent winner.

Columnist Conversations

Ahead of Wednesday's earnings report(pre open)GD is on its way to its best close of the year(new all time high...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.